Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

Inclusion Criteria: - Male or female, 1 year above or equal to age below 18 years at the
time of signing informed consent and below 18 years at the time of randomisation -
Diagnosed with type 1 diabetes mellitus (based on clinical judgement and supported by
laboratory analysis as per local guidelines) - Ongoing daily treatment with a basal-bolus
insulin regimen using basal insulin analogue or Neutral Protamine Hagedorn (NPH) insulin
for at least 90 days prior to the screening visit - HbA1c (glycosylated haemoglobin) below
or equal 9.5% (80 mmol/mol) analysed by the central laboratory at the screening visit
Exclusion Criteria: - More than one episode of diabetic ketoacidosis requiring
hospitalisation within the last 90 days prior to the screening visit - Treatment with any
medication for the indication of diabetes or obesity other than stated in the inclusion
criteria in a period of 90 days before screening